Ischemic stroke triggers a diversity of signaling pathways related to altered gene expression, inflammation, oxidative stress, mitochondrial function, and programmed cell death. The outcome of ischemic stroke depends on how early the blood flow can be restored and how early the related treatments can be provided. Although no one animal model can completely model the human disease, recent work has taken advantage of the many advances in molecular and cellular biology as tools to better understand the pathogenesis of stroke. Over the past 2 decades, only one treatment (thrombolytic therapy with rtPA) has been available in the United States for patients with acute stroke. However, a better understanding of the involved mechanisms should certainly lead to the identification of appropriate treatments.
Was this article helpful?